IGFBP3 and myeloid sarcoma: The first study investigating IGFBPs concentrations in MS patients revealed no differences in concentrations of IGFBP1, IGFBP2, and IGFBP3 in circulation and cerebrospinal fluid between MS patients and controls (64).